Search

Search Constraints

You searched for: Author/Creator Shetty, Aditya

Search Results

1. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. (9th November 2020)

2. 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. (9th November 2020)

3. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. (10th December 2020)

4. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. (9th November 2020)

6. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Issue 9 (27th July 2015)

10. Knowledge, attitude and practice of dental students and practitioners during the early days of COVID‐19 pandemic in India: A cross‐sectional study. Issue 11 (21st September 2021)